Govind Persad (also @govindpersad.bsky.social)
@GovindPersad
Followers
2K
Following
25K
Statuses
8K
Associate prof @UofDenver @SturmCOL, teaching #healthlaw. @StanfordPhil/@StanfordLaw/@NIHBioethics alum. Mastodon: https://t.co/C6dcWXG51P
Denver, CO
Joined August 2015
RT @ZekeEmanuel: Despite the efficacy of GLP-1s in treating obesity, the high cost of these drugs pose significant challenges for public he…
0
1
0
RT @AJKDonline: Association of Race and Ethnicity With High Longevity Deceased Donor Kidney Transplantation Under the US Kidney Allocation…
0
3
0
RT @leah_pierson: There are many more results in the paper, so check it out! (Feel free to email/DM me if you can…
0
5
0
RT @leah_pierson: Our article, Bioethicists Today: Results of the Views in Bioethics Survey (VIBeS), is now out in AJOB! We surveyed 824…
0
25
0
Using GLP-1 scarcity as a working example. Prof Ezekiel Emmanuel says allocation has been done in many countries without any thought to ethics. But if you’re 20 + have a BMI of >45 you may lose up-to 13 years of your life: if you are 70 + have a BMI >45 it is only 3. So what is fair? @BCEPShealth
0
0
0
RT @AParekhBPC: "Coverage for weight-loss drugs could reduce obesity immediately while less consumption of harmful foods could help prevent…
0
1
0
RT @ZekeEmanuel: In my latest for @WSJ, @GovindPersad & I argue that North Carolina’s decision to deny coverage for GLP-1 drugs like #ozemp…
0
4
0
RT @liebschutz: For Obese Patients, Wegovy Is Worth the Cost by @GovindPersad and @ZekeEmanuel via @WSJopinion
0
1
0
Here is another link if you have trouble accessing the op-ed
0
0
0
Some of the grant cases are patterned on litigation against non-health grantmakers (e.g. Atlanta's Fearless Fund) being brought by the same organization and attorneys that litigated the Harvard/UNC affirmative action cases:
0
0
0